Breaking News Instant updates and real-time market news.

NVTA

Invitae

$17.87

0.49 (2.82%)

07:34
05/31/19
05/31
07:34
05/31/19
07:34

Invitae to present research on germline multigene panel testing at ASCO meeting

Researchers from Invitae will present data that underscore the clinical utility of comprehensive genetic information for patients with breast, colorectal, prostate and pancreatic cancer to inform treatment decisions. Among the data, researchers will discuss findings showing that multigene germline genetic testing for breast cancer patients impacts patient outcomes and informs surgical strategy, precision medicine treatment and clinical trial eligibility. The studies will be presented at the American Society for Clinical Oncology Annual Meeting. A study of breast cancer patients conducted with researchers from the TME Breast Care Network, a network of more than 300 leading breast cancer physicians, evaluated germline genetic testing for 912 breast cancer patients, approximately half of whom met widely accepted clinical guidelines for testing and half of whom did not. Pathogenic/likely pathogenic germline variants were found in 8.65% of patients. Among patients with P/LP germline variants, 85% had variants in cancer-risk genes with established management recommendations and 80% had variants that made them eligible for clinical trials and/or precision medicine-based cancer treatments, such as PARP inhibitors. In 62% of patients with P/LP germline mutations, their clinicians reported the findings impacted their patients' outcomes. Another study presented at the meeting examined testing in colorectal cancer using multigene panels, and suggests one in five patients referred for genetic testing have clinically actionable germline variants, nearly half of which remain undetected when only a narrowly defined panel of the five mismatch repair genes are tested. Furthermore, some of these variants were in genes associated with known precision therapeutic implications or clinical trial eligibility, as well as established clinical management guidelines.Germline testing was performed on 9,000 patients with colorectal cancer and clinically significant variants were identified in 21% of patients. When only a limited genetic panel was used, 9% of patients had a pathogenic finding, which increased to 15% when 19 guidelines-based colorectal cancer genes were assessed. Using a comprehensive multigene panel, P/LP variants in genes with known precision therapy implications were detected in 14% of patients, and 17% had P/LP variants associated with established clinical management guidelines. These data add to the evidence supporting the value of comprehensive germline genetic testing for colorectal cancer patients to identify candidates for precision medical treatments and provide clinical guidance to at-risk family members.

  • 05

    Jun

  • 11

    Jun

  • 06

    Aug

NVTA Invitae
$17.87

0.49 (2.82%)

04/23/19
BNCH
04/23/19
NO CHANGE
BNCH
UnitedHealth preferred lab launch a long-term plus for Invitae, says Benchmark
Benchmark analyst Bruce Jackson noted that UnitedHealthcare (UNH) plans to launch a Preferred Laboratory Network to include Invitae (NVTA), which he views as a long-term positive for the latter and "another building block for Invitae's strategy to make genetic testing more widely available and more easily reimbursed." Other labs named to the preferred network include LabCorp (LH), Quest Diagnostics (DGX), and BioReference and GeneDx, which are both part of Opko (OPK), the analyst noted. UnitedHealthcare's current network includes NeoGenomics (NEO) and he doesn't anticipate any impact to NeoGenomics from the preferred network launch, added Jackson.
04/08/19
OPCO
04/08/19
NO CHANGE
Target $30
OPCO
Outperform
Invitae price target raised to $30 from $21 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter raised his price target for Invitae to $30 from $21 based on improved long-term competitive positioning for the company's patient-initiated testing given data presented at the ACMG meeting demonstrating poor performance for a leading DTC genetic test and potential consolidation in DTC market as industry matures and economies of scale, quality/clinical data and regulatory oversight drive market share. The analyst reiterates an Outperform rating on the shares.
03/04/19
03/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with an Outperform at SVB Leerink. 2. Invitae (NVTA) initiated with a Buy at Chardan. 3. Immunomedics (IMMU) initiated with a Buy at H.C. Wainwright. 4. Canopy Growth (CGC) initiated with a Neutral at Melius Research. 5. Alector (ALEC) initiated with an Overweight at Morgan Stanley and Barclays, an Outperform at SVB Leerink and Cowen, as well as a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/04/19
CHDN
03/04/19
INITIATION
Target $29
CHDN
Buy
Invitae initiated with a Buy at Chardan
Chardan analyst Steven Wardell initiated Invitae with a Buy and $29 price target. Wardell said Invitae is the cost and quality leader in the genetic testing market with a centralized testing and data strategy that positions the company to compete in this large, and attractive market. The analyst expects strong topline growth over the next three years and likes management's ability to execute and their confidence on where the sector is going and their place in it. He believes shares are mispriced versus peers given it is a growth leader among high-growth digital health companies.

TODAY'S FREE FLY STORIES

CGC

Canopy Growth

$43.70

0.92 (2.15%)

20:00
06/20/19
06/20
20:00
06/20/19
20:00
Earnings
Canopy Growth reports Q4 revenue $94.1M vs. $22.8M last year »

Reports Q4 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

WOPEY

Woodside Petroleum

$0.00

(0.00%)

19:47
06/20/19
06/20
19:47
06/20/19
19:47
Upgrade
Woodside Petroleum rating change  »

Woodside Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCLAY

Coca-Cola Amatil

$0.00

(0.00%)

19:40
06/20/19
06/20
19:40
06/20/19
19:40
Downgrade
Coca-Cola Amatil rating change  »

Coca-Cola Amatil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$247.78

-2.47 (-0.99%)

19:29
06/20/19
06/20
19:29
06/20/19
19:29
Periodicals
UnitedHealth to acquire Equian from New Mountain Capital, WSJ says »

UnitedHealth has reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 18

    Jul

KFY

Korn/Ferry

$48.61

1.04 (2.19%)

, EXEL

Exelixis

$21.14

0.15 (0.71%)

19:05
06/20/19
06/20
19:05
06/20/19
19:05
Hot Stocks
Fly Intel: After Hours Movers »

DOWN AFTER EARNINGS:…

KFY

Korn/Ferry

$48.61

1.04 (2.19%)

EXEL

Exelixis

$21.14

0.15 (0.71%)

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

PYPL

PayPal

$118.82

1.66 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

EXEL

Exelixis

$21.14

0.15 (0.71%)

, RHHBY

Roche

$0.00

(0.00%)

19:01
06/20/19
06/20
19:01
06/20/19
19:01
Hot Stocks
Exelixis informed by Genentech that IMspire170 did not meet primary endpoint »

In a regulatory 8-k…

EXEL

Exelixis

$21.14

0.15 (0.71%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 27

    Jun

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 02

    Sep

  • 04

    Nov

INVH

Invitation Homes

$27.68

-0.07 (-0.25%)

18:55
06/20/19
06/20
18:55
06/20/19
18:55
Syndicate
Invitation Homes 37.5M share Spot Secondary priced at ~$26.67 »

The deal priced for $1B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

MDB

MongoDB

$173.76

-0.33 (-0.19%)

18:44
06/20/19
06/20
18:44
06/20/19
18:44
Hot Stocks
MongoDB CEO: Every company is becoming a software company »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

VRML

Vermillion

$0.89

-0.1575 (-15.00%)

18:37
06/20/19
06/20
18:37
06/20/19
18:37
Hot Stocks
Vermillion adds two contracted agreements for OVA1 cancer risk test »

Vermillion has further…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$133.66

2.97 (2.27%)

18:34
06/20/19
06/20
18:34
06/20/19
18:34
Hot Stocks
Caterpillar CEO: We take a long-term view »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$247.78

-2.47 (-0.99%)

18:22
06/20/19
06/20
18:22
06/20/19
18:22
Periodicals
Breaking Periodicals news story on UnitedHealth »

UnitedHealth said to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 18

    Jul

BKS

Barnes & Noble

$6.71

0.055 (0.83%)

18:20
06/20/19
06/20
18:20
06/20/19
18:20
Downgrade
Barnes & Noble rating change at Gabelli »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$555.39

-0.78 (-0.14%)

18:11
06/20/19
06/20
18:11
06/20/19
18:11
Hot Stocks
CoStar Group acquires Off Campus Partners »

CoStar Group has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BDX

Becton Dickinson

$245.32

7.2 (3.02%)

17:55
06/20/19
06/20
17:55
06/20/19
17:55
Hot Stocks
Becton Dickinson backs safety of its Lutonix drug-coated balloons in SFA »

BD issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CPF

Central Pacific

$28.49

-0.13 (-0.45%)

17:41
06/20/19
06/20
17:41
06/20/19
17:41
Hot Stocks
Central Pacific authorizes buyback of up to $30M in common stock »

Central Pacific announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

AEL

American Equity

$27.51

0.3 (1.10%)

17:33
06/20/19
06/20
17:33
06/20/19
17:33
Hot Stocks
American Equity director Debra Richardson sells almost $2.2M in company shares »

American Equity director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

17:28
06/20/19
06/20
17:28
06/20/19
17:28
Earnings
Sealed Air backs FY19 adjusted EPS view $2.65-$2.75, consensus $2.73 »

Sealed Air continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

17:27
06/20/19
06/20
17:27
06/20/19
17:27
Hot Stocks
Sealed Air names James Sullivan as new CFO, effective June 24 »

Sealed Air announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJRD

Aerojet Rocketdyne

$43.01

1.49 (3.59%)

17:27
06/20/19
06/20
17:27
06/20/19
17:27
Hot Stocks
Aerojet Rocketdyne subsidiary awarded $140.18M missile defense modification »

Coleman Aerospace, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$43.68

-0.13 (-0.30%)

17:25
06/20/19
06/20
17:25
06/20/19
17:25
Hot Stocks
Sealed Air terminates CFO William Stiehl for cause, effective immediately »

Sealed Air announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBU

Brookfield Business Partners

$41.25

1.28 (3.20%)

, BAM

Brookfield

$48.38

0.29 (0.60%)

17:15
06/20/19
06/20
17:15
06/20/19
17:15
Syndicate
Brookfield Business Partners announces $795M equity offering »

Brookfield Business…

BBU

Brookfield Business Partners

$41.25

1.28 (3.20%)

BAM

Brookfield

$48.38

0.29 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

AXLA

Axcella

$10.39

0.27 (2.67%)

17:13
06/20/19
06/20
17:13
06/20/19
17:13
Earnings
Axcella reports Q1 EPS ($2.43), consensus (49c) »

Q1 operating expenses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LKSD

LSC Communications

$5.83

0.07 (1.22%)

17:11
06/20/19
06/20
17:11
06/20/19
17:11
Hot Stocks
LSC comments on DOJ action regarding proposed transaction with Quad »

LSC Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUAD

Quad/Graphics

$9.75

0.09 (0.93%)

, LKSD

LSC Communications

$5.83

0.07 (1.22%)

17:10
06/20/19
06/20
17:10
06/20/19
17:10
Hot Stocks
Quad/Graphics intends to defend proposed LSC Communications acquisition »

Quad/Graphics (QUAD)…

QUAD

Quad/Graphics

$9.75

0.09 (0.93%)

LKSD

LSC Communications

$5.83

0.07 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFM

Sprouts Farmers Market

$19.52

0.14 (0.72%)

17:04
06/20/19
06/20
17:04
06/20/19
17:04
Hot Stocks
Sprouts Farmers Market interim co-CEO/CFO Brad Lukow resigns »

Sprouts Farmers Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.